Suppression of Human Basophil Desensitization by Acetylsalicylic Acid  by Nakase, Yuko et al.
Allergology International Vol 63, No1, 2014 www.jsaweb.jp 127
Fig.　1　Histamine release by human basophils pretreated with ASA and/or 
CRA-1. Basophils were preincubated with 1 mM of ASA and/or 1 ng/ml of CRA-1 
for 2 hours at 37°C. Cells were then washed, primed with IL-3 at 300 pM for 
15 minutes and stimulated with either polyclonal anti-IgE antibody or MCP-1 
for 45 minutes. Supernatant histamine was measured using an autoanalyzer.7 
Percentage of release was calculated by subtracting the background release 
(<5% of total histamine). Data are the mean ± SEM of four separate experi-
ments using basophils from four different donors. *p < 0.05, versus correspond-
ing cells without preincubation with ASA.
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Dear Editor
Suppression of Human Basophil
Desensitization by Acetylsalicylic Acid
It is widely recognized that various internal and exter-
nal factors, such as fatigue, mental stress and drugs,
can affect the occurrence andor severity of allergic
reactions. Acetylsalicylic acid (ASA), commonly
known as aspirin, exacerbates symptoms of the upper
andor lower airways in sensitive individuals.1 In ad-
dition, clinical manifestation of food allergy is often
aggravated by prior intake of ASA, especially in sub-
jects with food-dependent, exercise-induced anaphy-
laxis (FDEIAn). A few mechanisms have been postu-
lated as underlying the effect of ASA on food allergy,
including that ASA augments histamine release from
mast cells and up-regulates the serum levels of aller-
gen molecules, presumably by increasing allergen ab-
sorption from the intestines.2,3 However, ASA’s role
in degranulation of human basophils remains contro-
versial, because there have been conflicting research
findings.3,4
In this study, we analyzed ASA’s effects on the
functions of human blood basophils. Basophils from
nonallergic volunteers were preincubated with 1 mM
of ASA at 37oC for 1-2 hours in Ca2+-containing PIPES
buffer, washed, and then stimulated with anti-IgE an-
tibody or other reagents such as monocyte chemoat-
tractant protein-1 (MCP-1), a chemokine. However,
the pretreatment with ASA caused no difference in
histamine release from the basophils. Next, we pre-
treated basophils with 1 mM of ASA plus 1 ngml of
an anti-FcεRI α-chain monoclonal antibody, CRA-1,
before stimulation with secretagogues.5 As shown in
Figure 1, basophils pretreated with CRA-1 underwent
desensitization, as indicated by decreased anti-IgE-
induced release of histamine compared to cells with-
out CRA-1 pretreatment. ASA partially altered CRA-1-
induced basophil desensitization, since anti-IgE-
induced histamine release was significantly higher in
cells pretreated with ASA plus CRA-1 compared to
cells pretreated with CRA-1 alone. MCP-1-induced de-
granulation was mildly enhanced by ASA, although
not with statistical significance, in CRA-1-pretreated
basophils. These results indicate that ASA affects de-
sensitization, but not direct degranulation, of human
basophils.
Previous studies have shown that relatively early
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signal transduction is involved in basophil desensiti-
zation, but the precise molecular mechanism(s) re-
mains unclear.6 ASA is a cyclooxygenase inhibitor,
and it is capable of blocking production of prostaglan-
din E2 (PGE2) . Our present results suggest that
either ASA-induced suppression of intracellular PGE2
levels or an imbalance of lipid mediators might down-
regulate the subcellular signal(s) involved in FcεRI-
mediated desensitization of basophils. From a clinical
point of view, desensitization modulation by ASA may
play a pathological role in clinical settings: basophils
exposed to low levels of an allergen would undergo
incomplete desensitization in the presence of ASA
and thus retain their sensitivity to the allergen. The
effective concentration of ASA on basophils (1 mM),
which was also active on mast cells, was slightly
higher than its therapeutic levels.2 ASA’s action may
target mainly local tissues, such as the intestines, that
contain migrated basophils, and blood basophils may
be weakly affected. ASA’s effect may augment the al-
lergic manifestation triggered by a gradually increas-
ing concentration of an allergen, a feature clinically
observed in food allergy. The results presented
herein and in previous reports collectively indicate
that ASA might enhance the in vivo action of food al-
lergens, presumably via multiple mechanisms, includ-
ing up-regulation of intestinal allergen absorption 3
and maintenance of basophil sensitivity to allergens
by suppressing desensitization.
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